Cannabis Use for Depression in Adolescents
(Cann-Teen Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to explore how cannabis affects brain function in adolescents dealing with depression. It specifically focuses on those who frequently use cannabis and those who don't use cannabis but are experiencing depression. Participants will undergo brain scans (neuroimaging investigation) over two years to help researchers understand any changes in brain activity. Teens who use cannabis regularly or have depression and are off certain medications might be a good fit for this study.
As an unphased study, this trial offers a unique opportunity to contribute to groundbreaking research that could improve understanding of adolescent brain health.
Will I have to stop taking my current medications?
If you are a depressed THC non-user, you must be free of psychotropic medications (drugs that affect mood, perception, or behavior) for more than 1 month before joining the study, or more than 3 months for medications with a long half-life like fluoxetine.
What prior data suggests that this neuroimaging investigation is safe for adolescents?
Research shows that cannabis use during adolescence can link to certain mental health risks. For instance, studies have found that starting cannabis use at a young age might increase the risk of developing psychotic disorders. However, not every teen who uses cannabis will experience these issues; only a small number may face long-term effects.
Past research has observed changes in brain size and connections in teens who use cannabis, as seen in brain scans. These changes, however, do not occur in everyone and can vary significantly among individuals.
Overall, while some risks are associated with cannabis use in teens, not every teen will encounter negative effects. The evidence suggests that some may be more at risk than others.12345Why are researchers excited about this trial?
Researchers are excited about the neuroimaging investigation for adolescent depression because it offers a novel way to understand how cannabis use affects the brain. Unlike traditional treatments that typically involve medications or therapy aimed at altering mood or behavior, this approach uses advanced imaging technology to visualize brain activity and structure over time. By doing so, it could uncover new insights into how cannabis might alleviate or worsen depression, potentially leading to more targeted and effective treatments in the future.
What evidence suggests that this neuroimaging investigation is effective for studying depression in adolescents?
Research has shown that using cannabis during the teenage years can affect brain function. Brain scans have revealed changes in the size and connections in the brains of teens who use cannabis. Some studies suggest a link between cannabis use and a higher risk of experiencing depression later in life. However, little direct evidence supports cannabis as a treatment for depression symptoms in teenagers. These findings focus on how cannabis affects the brain, not its use in treating depression. Participants in this trial will undergo neuroimaging to further explore these effects.46789
Who Is on the Research Team?
Vilma Gabbay, MD, JD, MS
Principal Investigator
University of Miami
Are You a Good Fit for This Trial?
This trial is for adolescents who use cannabis and are experiencing depression. Specific eligibility criteria have not been provided, but typically participants would need to meet certain age requirements and have a diagnosis of depression.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Neuroimaging Investigation
Participants receive neuroimaging investigation to study the effects of cannabis on brain function
Follow-up
Participants are monitored for safety and effectiveness after neuroimaging investigation
What Are the Treatments Tested in This Trial?
Interventions
- Neuroimaging Investigation
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Miami
Lead Sponsor
Nathan Kline Institute for Psychiatric Research
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator